167 related articles for article (PubMed ID: 16607967)
21. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
Bettahi I; Zhang X; Afifi RE; BenMohamed L
Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
[TBL] [Abstract][Full Text] [Related]
22. Immunology. Painful failure of promising genital herpes vaccine.
Cohen J
Science; 2010 Oct; 330(6002):304. PubMed ID: 20947733
[No Abstract] [Full Text] [Related]
23. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
24. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
[TBL] [Abstract][Full Text] [Related]
26. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.
Dropulic LK; Oestreich MC; Pietz HL; Laing KJ; Hunsberger S; Lumbard K; Garabedian D; Turk SP; Chen A; Hornung RL; Seshadri C; Smith MT; Hosken NA; Phogat S; Chang LJ; Koelle DM; Wang K; Cohen JI
J Infect Dis; 2019 Aug; 220(6):990-1000. PubMed ID: 31058977
[TBL] [Abstract][Full Text] [Related]
27. Review of mathematical models of HSV-2 vaccination: Implications for vaccine development.
Spicknall IH; Looker KJ; Gottlieb SL; Chesson HW; Schiffer JT; Elmes J; Boily MC
Vaccine; 2019 Nov; 37(50):7396-7407. PubMed ID: 29625767
[TBL] [Abstract][Full Text] [Related]
28. T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?
Posavad CM; Wald A; Hosken N; Huang ML; Koelle DM; Ashley RL; Corey L
J Immunol; 2003 Apr; 170(8):4380-8. PubMed ID: 12682275
[TBL] [Abstract][Full Text] [Related]
29. Summaries for patients. Condom use and genital herpes.
Ann Intern Med; 2005 Nov; 143(10):I40. PubMed ID: 16287786
[No Abstract] [Full Text] [Related]
30. Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection.
Mastrolorenzo A; Tiradritti L; Salimbeni L; Zuccati G
Int J STD AIDS; 1995; 6(6):431-5. PubMed ID: 8845402
[TBL] [Abstract][Full Text] [Related]
31. Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?
Dasgupta G; BenMohamed L
Vaccine; 2011 Aug; 29(35):5824-36. PubMed ID: 21718746
[TBL] [Abstract][Full Text] [Related]
32. Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.
Gottlieb SL; Giersing B; Boily MC; Chesson H; Looker KJ; Schiffer J; Spicknall I; Hutubessy R; Broutet N;
Vaccine; 2019 Nov; 37(50):7336-7345. PubMed ID: 28647165
[TBL] [Abstract][Full Text] [Related]
33. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
Corey L; Langenberg AG; Ashley R; Sekulovich RE; Izu AE; Douglas JM; Handsfield HH; Warren T; Marr L; Tyring S; DiCarlo R; Adimora AA; Leone P; Dekker CL; Burke RL; Leong WP; Straus SE
JAMA; 1999 Jul; 282(4):331-40. PubMed ID: 10432030
[TBL] [Abstract][Full Text] [Related]
34. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.
Awasthi S; Shaw C; Friedman H
Expert Rev Vaccines; 2014 Dec; 13(12):1475-88. PubMed ID: 25138572
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE
J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834
[TBL] [Abstract][Full Text] [Related]
36. Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?
Ghiasi H
J Virol; 2017 Dec; 91(23):. PubMed ID: 29138327
[No Abstract] [Full Text] [Related]
37. Potential prophylactic and therapeutic vaccines for HSV infections.
Ramachandran S; Kinchington PR
Curr Pharm Des; 2007; 13(19):1965-73. PubMed ID: 17627530
[TBL] [Abstract][Full Text] [Related]
38. Expression of the herpes simplex virus type 2 glycoprotein D in baculovirus expression system and evaluation of its immunogenicity in guinea pigs.
Fotouhi F; Soleimanjahi H; Roostaee MH; Dalimi Asl A
Iran Biomed J; 2008 Apr; 12(2):59-66. PubMed ID: 18506211
[TBL] [Abstract][Full Text] [Related]
39. Estradiol improves genital herpes vaccine efficacy in mice.
Pennock JW; Stegall R; Bell B; Vargas G; Motamedi M; Milligan G; Bourne N
Vaccine; 2009 Sep; 27(42):5830-6. PubMed ID: 19660586
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of herpes simplex virus type 1- and 2- specific antibodies among the acute, recurrent, and provoked types of female genital herpes.
Hashido M; Lee FK; Nahmias AJ; Kawana T
Microbiol Immunol; 1997; 41(10):823-7. PubMed ID: 9403510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
